

# INDEX

Note: Italicized page locators refer to exhibits.

- Absolute income hypothesis, *16*, 16–17, 29
- AC. *See* Average cost
- ACA. *See* Affordable Care Act
- Activities of daily living, 37
- Actuarially fair premium: loading factor and, 169; total wealth, expected wealth, and, 168
- Actuarially fair price: calculating, 161; definition of, 159
- Adverse selection, 166; definition of, 162; discouraging, methods for, 162; health insurance and, 92
- Advertising: oligopoly market and, 118
- Affordable Care Act, 14, 121, 189; Cadillac tax and, 5; equitable access and, 124–25; individual mandate and, 4; insurance industry and, 165–66; insurance mandate of, opting out of, 159; Medicaid eligibility under, 26; mitigation of adverse selection and, 93; preexisting conditions and, 165, 166; preventive health services and, 40, 189–90; states and Medicaid expansion under, 46
- Age: demand and, 92, 94
- Agency for Healthcare Research and Quality: Medical Expenditure Panel Survey, 178
- Alcohol consumption: elasticity of health and, 49, 50, 53
- Allocative efficiency: trade-off between technical efficiency and, 82
- American Community Survey, 17
- American Medical Association, 140
- Animal testing, 123
- Anthropogenic, definition of, 42
- Antimicrobial drugs, 38, 39
- Arc (midpoint) elasticity, 106
- Asymmetric information, 120–21
- ATC. *See* Average total cost
- Atlantic, The*, 5
- Auster, R., 50, 51

- AVC. *See* Average variable cost
- Average cost: quality and demand increases for monopolistically competitive physician and, 154, 154
- Average fixed cost: calculation example, 65, 65; short-run cost curve, 78
- Average product: definition of, 59; of labor, marginal product and, 59, 59
- Average total cost: short-run cost curve, 77, 78; in short-run costs of production, 66
- Average variable cost: short-run cost curve, 77, 78
- Backward-bending supply curve of labor: definition of, 147; physician labor supply and, 147–48, 148
- Balloon angioplasty, 62
- Barriers to entry, healthcare market and, 122
- Biological makeup: as health input, 42–43, 47
- Bonuses, 143
- Brand loyalty: monopolistic competition and, 119
- Brand-name drugs, 123
- Budget constraints, 97–101; indifference and demand curves linked to, 100–101, 101; optimal amounts of services to purchase, 99; price changes and, 100–101; rotation, as result of price increase, 100; sample, 98–99, 99; utility maximized to, 7, 8, 94
- Bureau of Labor Statistics, 177
- Buyers: healthcare, 88; in market, 87; monopolistic competition and, 119; monopsony structure and, 122; perfect competition and, 113; rational decisions and, 88
- Cadillac tax, 5
- Capitation, 142, 147
- Catastrophic care, 161
- CEA. *See* Cost-effectiveness analysis
- Centers for Medicare & Medicaid Services, 46
- Certificate of need, 122, 140; definition of, 122; laws, 122
- CHAMPVA. *See* Civilian Health and Medical Program of the Department of Veterans Affairs
- Chance node, in decision tree, 183
- Charge, 177
- Charity care, 141
- Children's Health Insurance Program (CHIP), 14, 45, 46, 161
- Cigarette smoking: elasticity of health and, 49, 50, 53
- Civilian Health and Medical Program of the Department of Veterans Affairs, 46, 47
- Clinical health outcomes: in cost-effectiveness analysis, 179
- Clinical trials: stages in, 123
- CMS. *See* Centers for Medicare & Medicaid Services
- Coinsurance: definition of, 161; demand and various levels of, 106; moral hazard effects and, 164, 166
- Coinsurance rates: demand curve and, 105, 105; pharmaceutical demand and, 108; utilization of physician services and, studies on, 106–7
- Community wealth theory, 22
- Competition: in insurance market, 165; measuring in insurance market, 170–71; monopolistic, 132, 134
- Competitive markets: deviation from, 120–23

- Complementary goods and services, 96;  
definition of, 90; demand and  
decrease in price of, 104
- CON. *See* Certificate of need
- Constant returns to scale, 81–82
- Consumer loyalty: monopolistic competi-  
tion and, 119
- Consumer perspective, 179
- Consumer price index, 177
- Consumers, 3; definition of, 6; health eco-  
nomics assumptions about, 6–7
- Consumer surplus: definition of, 130
- Copayments: cost consciousness and, 161;  
demand and, 104–5
- Cost–benefit analysis, 175
- Cost-effectiveness analysis, 173–91; clini-  
cal health outcomes and, 179; cost  
component of, tasks within, 176–78,  
181; definition of, 174, 181; health-  
related quality of life and, 180;  
incremental, tasks and components  
in, 176–78; interpreting results of,  
180, 180–81; limitations of, 174,  
190; matrix for comparing alterna-  
tive interventions, 175; Oregon  
Medicaid program and use of, 190;  
perspective and, 178–79; policy  
decisions and use of, 189–90; proba-  
bilities and, 189, 190; quality-  
adjusted life year and, 179–80;  
scenarios in, 175; sensitivity analyses  
and, 189; target population and, 176
- Cost-effectiveness analysis, flu vaccine,  
182–89, 188; complete decision tree  
with costs and probabilities for flu  
vaccine, 184; costs of flu vaccine,  
182; decision tree for supportive care  
*vs.* flu vaccine, 183; flu vaccine (lower  
arm of decision tree), 185–86; incre-  
mental cost-effectiveness ratio in,  
186, 188–89; person-years for  
unvaccinated cohort, 187; person-  
years for vaccinated cohort, 187;  
person-years in, 186; quality adjusted  
life expectancy in, 187–88, 188;  
quality-adjusted life year in, 188,  
188; supportive care (upper arm  
of decision tree), 183, 185; unvacci-  
nated group, 186; vaccinated  
group, 186
- Cost-minimization analysis, 175
- Cost of health production, 73–80; isocost,  
73, 74; isoquant, 73, 74; isoquants  
and no input substitution, 74;  
isoquants and perfect input  
substitution, 74–75; marginal cost,  
average total cost, and average  
variable cost, 77–79; short-run costs,  
75–77
- Cost(s): average, 154, 154; average fixed,  
65, 65, 66, 78; average total, 66, 77,  
78; average variable, 77, 78; eco-  
nomic, 65; fixed, 64; long-run, 65,  
68; marginal, 66, 152, 152, 153,  
154, 154; monopolistic competition  
and, 119; opportunity, 65; produc-  
tion and, 64–66; relationship  
between marginal product and, 77;  
short-run, 65, 66, 66; time, calculat-  
ing, 177–78; total, 60, 64; total  
fixed, 65, 65; typical, for health-  
related goods and services, 158;  
variable, 64
- Cost-to-charge ratio, 177, 178
- CPI. *See* Consumer price index
- Darsky, B. J., 108
- Deadweight social loss, 131, 131
- Decile: definition of, 24
- Decision node, in decision tree, 183

- Decision tree: in cost-effectiveness analysis of flu vaccine, 182–83, 183, 184, 185; symbols in, 183
- Decreasing returns to scale, 82
- Deductibles: definition of, 161; moral hazard effects and, 164, 166
- Demand: age and, 92, 94; copayment and effect on, 104–5; decrease in price of substitute service and effect on, 89, 89; definition of, 86; education and, 91, 94; factors affecting, 2; for healthcare, 85–109; for health insurance, 161; for health insurance, factors affecting, 163–65; health status and, 91, 94; income and, 90–91, 94; inelastic, 106; insurance and, 92–93, 94; law of, 88; pharmaceutical, 108; price and, 88–90, 94; price elasticity of services and, 108, 109; quality of care and, 91, 94; supplier-induced, 145–46; tastes and preferences and, 92, 94; time and, 90, 94; understanding, importance of, 87. *See also* Elasticity of demand
- Demand curve(s): change in price of substitutes and complements and, 103, 104; indifference curves linked to, 101; of monopolistically competitive structure, 132, 132; nerve compression treatment, price insensitivity, and, 133; price change and movement along, 101, 102, 109; shifts in, 102–3; with and without health insurance, 105
- Demand–price relationship, 86–87, 87
- Demand uncertainty: oligopoly market and, 118
- Deprivation: definition of, 25
- Deprivation hypothesis, 16, 25–26
- Diagnosis-related group, 178
- Diminishing returns: in production, reasons for, 59–60
- Discount rate: cost-effectiveness analysis and, 177
- Diseconomies of scale, 81
- Disutility, 90
- Diversification: reimbursement rates and, 140
- DRG. *See* Diagnosis-related group
- Duopoly, 113, 114, 115, 117
- Econometrics, 3
- Economic analysis: health policy linked to, 4–5, 6
- Economic costs, 65
- Economic relationships, 3–4
- Economics: in everyday life, 2
- Economies of scale, 67–68, 80
- Economies of scope, 68
- Economist: definition of, 2, 6  
*Economist, The*, 5
- Education: demand and, 91; as health input, 43–44; health–wealth relationship and, 12
- Efficiency: goods and services and, 124–25
- Elasticity: midpoint, 106; point, 106
- Elasticity of demand, 105–6, 134; price, monopoly structure, and, 132; private insurers and, 161
- Elasticity of health: definition of, 49, 53; expenditure, research on, 52; interpreting elasticity results, 50
- Elasticity of substitution, 71–73, 82; calculating, 72; definition of, 72; evaluated at the mean, 73; studies on, 72
- Elective procedures: health insurance and, 93
- Emergency departments, 124

- Emergency Medical Treatment and Active Labor Act, 117
- Empirical analysis: health–wealth relationship and, 21
- Employers: health insurance obtained through, 164
- EMTALA. *See* Emergency Medical Treatment and Active Labor Act
- End-of-life care: small area variation and, 144
- Environment: as health input, 41–42, 47; health–wealth relationship and, 12
- Equilibrium output: perfect competition and, 126
- Equilibrium price, 88; definition of, 7; perfect competition and, 126
- Equilibrium quantity, 7, 88
- Equity: goods and services and, 124–25
- Ettner, Susan, 21
- Exercise, 41
- Expected utility, 171; definition of, 169; risk and, 168–69
- Expected wealth: definition of, 168
- Expenditure elasticity of health: research on, 52
- Externalities, 130–31; negative, 122; perfect competition and lack of, 115; positive, 122
- Fairman, K. A., 108
- Federal poverty level: critical level of income and, 25–26
- Federation of State Medical Boards, 87
- Fee-for-service, 142; economic incentives and, 143, 147; supplier-induced demand and, 145; supplier-induced demand theory and, 149
- Financial incentives: capitation, 142, 143; copayments, deductibles, and, 161; fee-for-service method, 142, 143, 143, 147; salaries, 143
- Fixed costs, 64; profit level, shut-down point, and, 80
- Flu vaccine: complete decision tree with costs and probabilities for, 184; cost-effective analysis example, 182–83, 185–89; costs of, 182; decision tree for supportive care *vs.*, 183; person-years for unvaccinated cohort, 187; person-years for vaccinated group, 187; quality-adjusted life expectancy (unvaccinated group), 188; quality-adjusted life expectancy (vaccinated group), 188
- Food and Drug Administration, 87
- For-profit businesses: profit distribution to shareholders, 141; profits and, 64; taxes and, 141
- Freedom of entry and exit: perfect competition and, 113
- Free market: definition of, 87
- Fuchs, V. R., 50
- Garner, D. D., 108
- GDP. *See* Gross domestic product
- Gender: biological and genetic health determinants and, 42
- Generic drug manufacturers: marginal cost of production and, 124
- Generic drugs, 123
- Genetic factors: as health input, 42–43, 47
- Gini coefficient: measuring inequality of wealth and, 23, 24
- GNP. *See* Gross national product
- Goldman, D. P., 108
- Goods and services, health-related: budget constraints and, 97–101; complementary, 90, 96–97; efficiency, equity, and, 124; insurance and demand for,

- 92; law of demand and, 88; preventive, health status and demand for, 91; related, price of, 89; supplier-induced demand and, 145; utility and, 6–7
- Government: monopolies and, 116
- Government insurance programs, 161; Children's Health Insurance Program, 45, 46; Civilian Health and Medical Program of the Department of Veterans Affairs, 46, 47; as health input, 45–47; Indian Health Service, 46, 47; Medicaid, 45, 46; Medicare, 45, 46; TRICARE, 45, 47
- Gradient: definition of, 15
- Great Recession: effects of, economic analysis, 5
- Greenlick, M. R., 108
- Gross domestic product: health improvements, lowered income inequality, and, 29; medical expenditures as percentage of, 36; per capita, health indicators and, 27; strength of economy and, 28
- Gross national product: nonlinear relationship between life expectancy and, 28–29, 29; strength of economy and, 29
- Group insurance: supply and, 165
- Group practice: benefits of working in, 138, 146; economies of scope and scale in, 138; market power and, 138; physicians' transition from solo practice to, 137–38
- Hadley, J., 51
- Happiness: utility and, 6, 94
- Health: elasticity of, 49; subjective measures of, 37–38. *See also* Production of health
- Health Affairs*, 5
- Healthcare: buyers and sellers of, 88; insurance and reduced out-of-pocket costs for, 92; market power in, 139. *See also* Demand for healthcare; Goods and services, health-related
- Healthcare decisions: insured individuals and, 164
- Healthcare expenditures: continuous rise in, 36
- Healthcare market: barriers to entry, 122; supply-and-demand model applied to, 128, 128–30, 129
- Healthcare providers: technology adoption and, 63
- Health economists: questions formulated by, 3
- Health expenditures: elasticity of health and, 49, 50, 53
- Health inputs, 36, 38–47; biological makeup, 42–43, 47; education, 43–44, 47; environment, 41–42, 47; government programs, 45–47; housing, 44–45, 47; income, 43; income–health relationship, 43; law of diminishing returns and, 39–40; lifestyle, 40–41; medical-based, 38; nonlinear relationship between health status and, 48, 48, 52
- Health insurance: adverse selection and, 92, 162; demand and, 92–93, 94, 161; demand curves with and without, 105; factors affecting demand for, 163–65; financing structure, 161; moral hazard and, 93, 164; predictability factor and, 158; premiums, 40; price sensitivity and, 104, 105, 105; RAND Health Insurance Experiment, 52, 107, 108, 109; unequal distribution of income

- and unequal access to, 23; utility and purchase of, 168–69; wealth and access to, 11, 11, 43, 47
- Health insurance companies, 88
- Health insurance industry: oligopoly structure and, 118, 125
- Health insurance premiums: Affordable Care Act, adverse selection, and, 93; definition of, 160; risk pooling and, 159–60
- Health literacy, 12
- Health maintenance organizations, 107
- Health output, 57–58
- Health policy: economic analysis linked to, 4–5, 6
- Health production. *See* Cost of health production; Production of health
- Health production function, definition of, 48
- Health programs: quality-adjusted life years and, 38
- Health-related quality of life, 180; in cost-effectiveness analysis, flu vaccine, 187, 188, 190
- Health state: contextualizing, 179–80
- Health status: bidirectional relationship between income level and, 12, 13, 13; community wealth theory and, 22; concave relationship between income level and, 20, 20–21; demand and, 91, 94; elasticity of health and, 49; health production function and, 48; investing in education and, 44; linear relationship between income level and, 13, 14; measuring, 37–38, 47; nonlinear relationship between health inputs and, 48, 48, 52; nonlinear relationship between income level and, 15, 15; position within community and, 26; shifts in demand curve and, 102, 103, 103
- Health–wealth relationship: dynamics within, 11–13; graphing, 13; international studies on, 27–29. *See also* Income–health theories
- Healthy People 2020, 42
- Herd immunity, 122, 130
- Herfindahl-Hirschman Index (HHI): calculating, 170–71
- HIV status: biological and genetic health determinants and, 42
- HMOs. *See* Health maintenance organizations
- Homogeneous products: perfect competition and, 114
- Hospitals: cost-to-charge ratios, 178; profit level and shut-down point for, 79–80
- Housing: as health input, 44–45
- HRQL. *See* Health-related quality of life
- Hypotheses: drawing firm conclusions about, 25
- ICER. *See* Incremental cost-effectiveness ratio
- Immunization: herd immunity and, 122, 130
- Incentives. *See* Financial incentives
- Incidence: definition of, 37
- Income: demand and, 90–91, 94; demand for health insurance and, 163; as health input, 43; of physicians, 147; shifts in demand curve and, 103
- Income distribution and health, at the national level, 18
- Income effect, 89; physician labor supply and, 147–48, 154
- Income–health relationship, 43

- Income–health theories, 15–18, 16;  
 absolute income hypothesis, 16,  
 16–17, 20–22; deprivation hypothe-  
 sis, 16, 25–26; income inequality  
 hypothesis, 16, 22–25; relative  
 income hypothesis, 16, 17–18, 22;  
 relative position (or rank) hypothe-  
 sis, 16, 26–27
- Income inequality: results of studies on, 25
- Income inequality hypothesis, 16, 22–25;  
 definition of, 23; studies not sup-  
 portive of, 25; studies supportive of,  
 25
- Income level: bidirectional relationship  
 between health status and, 12, 13,  
 13; concave relationship between  
 health status and, 20, 20–21; linear  
 relationship between health status  
 and, 13, 14; nonlinear relationship  
 between health status and, 15, 15
- Increasing returns to scale, 81
- Incremental cost-effectiveness ratio, 176,  
 180, 181; in cost-effectiveness  
 analysis, flu vaccine, 186, 188–89;  
 denominator in, 186, 190; numerat-  
 or in, 186, 190
- Indifference curve(s): for complements, 96,  
 96–97; definition of, 94; linking to  
 budget constraints, 100; linking to  
 demand curves, 101; negative slope  
 of, 95; as straight lines or bent  
 toward the origin, 96; for substitutes,  
 97, 97; three, indifference map with,  
 95; utility constant along, 94–95
- Indifference map: definition of, 95; with  
 three indifference curves, 95
- Inelastic demand, 106
- Inequality of wealth: Gini coefficient and,  
 23, 24; Lorenz curve and, 24, 24;  
 measuring, 23–24
- Infant mortality rate: definition of, 37;  
 gross domestic product per capita  
 and, 27
- Information: asymmetric, 120–21
- Inherited conditions, 42–43
- Inputs: technology and productivity of, 61
- Input substitution, 58
- Inquiry*, 5
- Insurance. *See* Health insurance
- Insurance companies: reimbursement  
 rates, physicians' market power, and,  
 139
- Insurance market, 157–72; Affordable  
 Care Act and, 165–66; competition  
 in, 165; insurance process, 160–62;  
 loading factor and, 169; measuring  
 competition in, 170–71; risk and  
 uncertainty, 158–60; risk aversion  
 and utility and, 167–69; risk lovers  
 and, 169–70
- Insurance policies: purpose of, 158–60, 166
- Interdependence, oligopoly market and, 118
- Internet: medical information and, 137
- Interventions: comparing economic worth  
 of, 175, 175; incremental cost-  
 effectiveness ratio and, 176, 180, 181
- Isocost: definition of, 73
- Isocost–isoquant diagram, 74
- Isoquant: definition of, 73; no input sub-  
 stitution and, 74, 75; perfect input  
 substitution and, 74–75, 75
- Jensen, G. A., 72
- Joyce, G. F., 108
- Kindig, D., 72
- Labor: marginal product of, 72, 72; sub-  
 stitutability of, 72, 73. *See also*  
 Physician labor supply



- Latex gloves: market shortage caused by increased demand for, 128, 128
- Law of demand: definition of, 88
- Law of diminishing marginal productivity, 71
- Law of diminishing marginal utility, 96
- Law of diminishing returns, 39–40, 58
- Lead-based paint, 45
- Leveson, I., 50, 51
- Libby, D., 72
- Life expectancy: nonlinear relationship between gross national product and, 28–29, 29; in United States, 37
- Lifestyle: adverse selection and, 92; demand and, 92, 94; as health input, 40–41, 47; health–wealth relationship and, 12; production of health and, 51, 53
- Loading factor, 161, 169
- Long-run average total cost (LRAC) curve, 80, 81
- Long-run costs: definition of, 65; of production, 68
- Lorenz curve: measuring inequality of wealth and, 23, 24, 24
- Loss potential: magnitude of, demand for health insurance and, 163
- Managed care: technology and, 63
- Marginal cost, 66; declining demand for monopolistically competitive physician and, 153, 153; monopolistically competitive physician and, 152, 153; price discrimination and, 151, 152; quality and demand increases for monopolistically competitive physician, 154, 154; short-run cost curve, 78; short-run costs of production, 66
- Marginal cost curves: marginal product and, 79, 79
- Marginal private benefit, 130, 130
- Marginal product, 39, 47; average product of labor and, 59, 59; diminishing returns and, 58–60; of health inputs, diminishing, 49; health program funding and, 49; of labor, 72, 72; marginal cost curves and, 79, 79; profit and, 60–61, 61; relationship between costs and, 77
- Marginal productivity: short-run marginal cost and, 77
- Marginal rate of substitution, 99, 109
- Marginal revenue, 126; declining demand for monopolistically competitive physician and, 153, 153; monopolistically competitive physician and, 152, 153; price discrimination and, 151, 152; quality and demand increases for monopolistically competitive physician and, 154, 154
- Marginal social benefit, 131, 131
- Marginal utility: graphical representation of, 167, 168
- Marginal utility of income: definition of, 167; lack of uniformity in, 167
- Market: definition of, 87; free, 87
- Market concentration: definition of, 141
- Market labor supply curve: physician labor supply curve *vs.*, 148
- Market power: definition of, 138; in healthcare, 139
- Market power, of physicians: forms of, 138–41; group practice and, 138; higher reimbursement rates and, 139; lower price and, 139–40; market concentration and, 141; regulations and, 140; tax advantage and, 141

- Market structure(s): categorizing, 113; cost of differentiation, 119–20; duopoly, 114, 115, 117; monopolistic competition, 114, 115, 119; monopoly, 114, 115, 116–17; monopsony, 114, 122–23; oligopoly, 114, 115, 117–18; perfect competition, 113–14, 114; in pharmaceutical industry, 123–24, 125; types of, 114
- Market supply: definition of, 87
- MC. *See* Marginal cost
- Medicaid, 6, 14, 45, 46, 137, 144; deprivation hypothesis and, 26; financing mechanism for, 161; introduction of, 129; prospective payments, 64; reimbursement rates, 140
- Medical-based inputs, 38, 47
- Medical care: quality and rising price of, 152–54
- Medical Expenditure Panel Survey (Agency for Healthcare Research and Quality), 178
- Medical expenditures: continuous rise in, 36; study on production of health and, 51
- Medical technology, 38, 39; definition of, 61; rising physician prices and, 152
- Medicare, 6, 45, 46, 144; diagnosis-related groups, cost-to-charge ratios, and, 178; financing mechanism for, 161; introduction of, 129; prospective payments, 64; reimbursement rates, 140
- Medicare Payment Advisory Commission (MedPAC), 4
- Microeconomics: fundamental assumptions in, 6–8; health economics rooted in, 6
- Midpoint elasticity, 49–50, 106
- Milbank Quarterly*, 5
- Monopolistically competitive market structure: physicians and, 142, 147
- Monopolistically competitive physicians: decline in demand and, 153, 153; perfectly competitive price and, 152, 153; quality and demand increases for, 154, 154
- Monopolistically competitive structure, 132, 134; long-run monopolistically competitive firm, 133; short-run, monopoly structure and, 132
- Monopolistic competition, 114, 115; characteristics of, 119; definition of, 115
- Monopoly, 113, 114, 115, 125; pharmaceutical market as example of, 124; reasons for, 116; structure of, 132, 132
- Monopsony, 114, 122–23
- Moral hazard: health insurance and, 93; insurance market and, 164, 166
- Morbidity: definition of, 37
- Morgenstern, Oskar, 167
- Morrisey, M. A., 72
- Mortality: relative income and, 23; results of studies on, 25; studies on effect of income on, 21; Whitehall Study of, 27
- Motheral, B., 108
- MR. *See* Marginal revenue
- MRS. *See* Marginal rate of substitution
- Multispecialty groups: benefits of, 138; economies of scope and scale in, 138
- Narrow distribution of income: health status and, 18
- National Health Service (United Kingdom): excess demand in zero copayment market and, 128, 129, 130
- Negative externality, 115, 122
- Neighborhood condition: health outcomes and, 45

- Nerve compression treatment: potential, price insensitivity and demand curve for, 133
- Nevada: research on death rates in, 50
- New drug approval: costs related to, 123
- New York City: median household income in, 17
- New York Times*, 5
- No input substitution: isoquants and, 74, 75
- Non-health-related subjects: examples of, 4
- Normal good, 91
- Not-for-profit businesses: reinvestment of profits and, 7, 64, 141; tax advantages for, 141
- Nurses: substitutability of labor and, 72, 73
- Obesity, 43, 44
- Occupational rank and health: Whitehall Study findings on, 27
- Oligopoly, 113, 114, 115, 117–18; characteristics of, 118; definition of, 115, 118; pharmaceutical market as example of, 124
- Opportunity cost, 65
- Oregon: cost-effectiveness analysis and Medicaid program in, 190
- Out-of-pocket healthcare costs: health insurance, predictability factor, and, 158; insurance and reduction in, 92; moral hazard and, 93
- Output: under perfect competition, 125–27
- Oversaturation: certificate of need and, 140
- Patent: definition of, 124
- Payers, 3; definition of, 6; health economics assumptions about, 7–8
- Payment cross-subsidization, 144
- Payment methods, physician, 142–44; capitation, 142, 143, 147; cross-subsidization, 144; fee-for-service, 142, 143, 143, 147; salary, 143
- Perfect competition, 114; deviation from, 120–23; firm taking a price from the industry, 126, 126; impact of profits on market activity, 127, 127; nonexistence of externalities in, 122; operating conditions in, 113–14; short-run price and output under, 125–27
- Perfect complements: definition of, 97; indifference curves for, 96
- Perfect input substitution: isoquants and, 74–75, 75
- Perfect knowledge, 114
- Perfectly competitive markets: physicians and, 141; pricing mechanism in, 8
- Perfect substitutes: indifference curves for, 97
- Person-years: cost-effectiveness analysis, flu vaccine, 186, 187
- Perspective, 178–79
- Pharmaceutical demand, 108
- Pharmaceutical industry: market structure in, 123–24, 125
- Physician agent, 146
- Physician assistants: substitutability of labor and, 72, 73
- Physician behavior, 136–56; market power for physicians, 138–41; payment methods, 142–44; physician labor supply, 147–48; physicians as monopolistically competitive, 141–42, 152, 153, 153, 154, 154; rising physician prices, role of quality in, 152–54; small area variation, 144–45; supplier-induced demand, 145–46; supplier-induced demand theory and, 148–51; transition from solo to group practice, 137–38

- Physician fees: competitive model and, 129
- Physician-induced demand, 145
- Physician labor supply: backward-bending supply curve of labor and, 147–48
- Physician prices: rising, role of quality in, 152–54
- Physicians: MedPAC and pricing differential for, 4–5; as monopolistically competitive, 141–42, 147, 152, 153, 153, 154, 154
- Physician-to-population ratio, 149–50, 154; increase in labor supply and, 149, 150
- Point elasticity, 106
- Policymakers: understanding demand and, 87
- Policymaking process: cost-effectiveness analysis and, 189–90; economic analysis and, 4–5
- Pollution: health and impact of, 42
- Population-level measures, 37
- Position: health status and, 26
- Positive externality, 115, 122
- PPF. *See* Production possibility frontier
- Preexisting conditions: Affordable Care Act and, 165, 166
- Preferences. *See* Tastes and preferences
- Preference scores, 180
- Premiums. *See* Health insurance premiums
- Prescription drugs: brand-name, 123; demand and, 108; generic, 123; patent protection for, 124
- Present value: cost-effectiveness analysis and, 177; technology adoption and, 62
- Preventive care: Affordable Care Act and, 40, 189–90; health status and demand for, 91
- Price: budget constraint and changes in, 100–101; demand and, 88–90, 94; demand for health insurance and, 163; duopoly structure and, 117; health-related goods and services and, 86, 89–90; monopoly structure and, 116; movement along demand curves and change in, 101, 102, 109; oligopoly market and, 118; in perfectly competitive market, 8
- Price discrimination: supplier-induced demand theory and, 150–51
- Price elasticity: definition of, 105; of demand, 105–6, 109
- Price negotiations: private health insurance companies and, 64
- Price of complement: shifts in demand curve and, 103
- Price of substitute: shifts in demand curve and, 102–3
- Price sensitivity: demand for healthcare and, 104; demand for healthcare and, literature review of, 106–8; monopoly structure and, 132; physician-segmented practices and, 151
- Price setters: monopolistic competition and, 119
- Price setting: physicians' market power and, 139–40
- Price takers: perfect competition and, 114
- Principal–agent relationship, 146
- Private health insurance companies: price negotiations and, 64
- Private perspective, 178, 179
- Probabilities: cost-effectiveness analysis and, 189, 190
- Probability of healthcare event: demand for health insurance and, 163

- Producers, 3; definition of, 6; health economics assumptions about, 7
- Producer surplus: definition of, 130
- Product differentiation, 121; oligopoly market and, 118
- Production: cost and, 64–66; definition of, 71
- Production costs: monopolistic competition and, 119
- Production function: definition of, 48, 71; elasticity of substitution and, 71–73
- Production of health, 35–53; factors influencing, 39; health inputs, 36, 38–47; input–output relationship and, 57–58; literature on, review of, 49–52; measuring health status, 37–38; seminal studies, 50–52
- “Production of Health: An Exploratory Study” (Auster, Leveson, and Sarachek), 50
- Production possibility frontier, 69–71; definition of, 69; sample, 69
- Profit(s): bonuses and, 143; cost curves and, 80; definition of, 60; determining, in the short run, 127; impact of, on market activity, 127, 127; marginal product and, 60–61, 61; monopolistic competition and, 119; shut-down point and level of, 79–80; taxes and, 141
- Prospective payments, 64
- Protease inhibitors, 62
- Provider substitution: unintended consequences of, 98
- Public health, 38, 39
- Public policy: informing, with stable results, 25, 29
- QALE. *See* Quality-adjusted life expectancy
- QALY. *See* Quality-adjusted life year
- Quality: rising physician prices and, 152–54
- Quality-adjusted life expectancy: in cost-effectiveness analysis, flu vaccine, 187–88, 188
- Quality-adjusted life year, 37, 38; in cost-effectiveness analysis, flu vaccine, 188, 188; cost-effectiveness analysis and, 179–80, 181; effectiveness measured in, 176
- Quality of care: demand and, 91, 94
- Quantity demand: inverse relationship between price and, 88
- RAND Health Insurance Experiment, 52, 107, 108, 109
- Rational decisions: marketplace dynamic and, 88
- Real income, 88
- Regulations: physicians’ market power and, 140
- Reimbursement rates: diversification and, 140; physicians’ market power and, 139
- Relative income hypothesis, 16, 17–18; definition of, 17; individual health and, 22
- Relative position (or rank) hypothesis, 16, 26–27; definition of, 26; mathematical explanation of, 27; research studies on, 27
- Relative price, 88
- Residents: substitutability of labor and, 72, 73
- Returns to scale: constant, 81–82; decreasing, 82; increasing, 81
- Revenue formula, 89
- Revenue levels: monitoring, 141
- Riportella-Muller, R., 72

- Risk: estimating, 162; expected utility and, 168–69; health insurance market, uncertainty, and, 158–60
- Risk averse: definition of, 158
- Risk aversion, 171; demand for health insurance and, 163, 166; utility and, 167–69
- Risk lovers: health insurance and, 159; marginal utility of wealth for, 170
- Risk-neutral individuals: health insurance and, 159
- Risk pools, 159–60; adverse selection and, 162; low- and high-risk groups in, 160
- Risk premium (loading factor), 169
- Salaries: elasticity-of-substitution example, 71; physician payment methods and, 143
- Sarachek, D., 50, 51
- SATC curve. *See* Short-run average total cost curve
- Satisfaction: utility and, 6, 94
- SAV. *See* Small area variation
- Scale: in economics, 67
- Scitovsky, A. A., 106, 107
- Sedentary lifestyle: illness and, 43
- Self-assessed health: empirical analysis of, 21
- Self-insurance, 163
- Sellers: healthcare, 88; in market, 87; monopolistic competition and, 119; rational decisions and, 88
- Sensitivity analyses, 189
- Shareholders: profit distribution to, 141
- Short-run average total cost curve, 80, 80
- Short-run cost, 65, 75–77; curves, 77, 78; of production, 66, 66
- Short-run marginal cost: curve, 80; marginal productivity inversely related to, 77
- Short-run price: under perfect competition, 125–27
- Short-run total cost: curve, 76; increasing hospital services and, 76
- Shut-down point: profit level and, 79–80
- Sleep, 41
- Small area variation, 144–45
- SMC. *See* Short-run marginal cost
- Smith, M. C., 108
- Smoking, 41
- SNAP. *See* Supplemental Nutrition Assistance Program
- Snyder, N., 106, 107
- Social capital: definition of, 41
- Social perspective, 179
- Solo practice: physicians' transition to group practice from, 137–38
- Stable results, in research studies, 25
- States: Affordable Care Act and Medicaid expansion in, 46; highly concentrated insurance markets in, 171
- Sticky prices: oligopoly market and, 118
- Substitute goods or services: indifference curves for, 97, 97; price, demand, and, 89, 89, 104
- Substitution: input, 58; marginal rate of, 99; no input, isoquants and, 74, 75; perfect input, isoquants and, 74–75, 75; unintended consequences of, 98. *See also* Elasticity of substitution
- Substitution effect: definition of, 89; physician labor supply and, 147–48, 154
- Supplemental Nutrition Assistance Program, 14
- Supplier-induced demand, 145–46, 147; definition of, 145; physician agent and, 146; target income hypothesis and, 146

- Supplier-induced demand theory, 148–51;  
physician-to-population ratio, 149–  
50; price discrimination, 150–51, 152
- Supply: group insurance and, 165
- Supply-and-demand model, 134; applying  
to healthcare markets, 128, 128–30,  
129; externalities and, 130–31
- Supply oversaturation: certificate of need  
and, 140
- Target income hypothesis, 146
- Target population: cost-effectiveness  
analysis and, 176
- Tastes and preferences: demand and, 92,  
94; shifts in demand curve and, 103
- Taxes: demand for health insurance and,  
164; physicians' market power and,  
141; public or government insurers  
and, 161
- Technical efficiency: trade-off between  
allocative efficiency and, 82
- Technological change: ripple effects of,  
examples, 62
- Technology: adoption, 62–63; managed  
care and, 63; production and, 61–63
- Terminal node, in decision tree, 183
- TFC. *See* Total fixed cost
- Thailand: gross domestic product per cap-  
ita and infant mortality rate in, 27
- Therapeutic class of prescription drugs, 124
- Third-party payers, 137
- Thornton, J., 51
- Time: demand and, 90–91, 94
- Time cost, calculating, 177–78
- Total cost, 64; definition of, 60; in short-  
run costs of production, 66
- Total fixed cost: calculation example, 65,  
65; in short-run costs of production,  
66
- Total profit formula, 60
- Total revenue formula, 60
- Total variable cost: in short-run costs of  
production, 66
- Travel time: demand for healthcare and, 90
- Treatment options: small area variation and,  
144–45
- TRICARE, 45, 47
- TVC. *See* Total variable cost
- Uncertainty, 121, 169; demand for health  
insurance and, 163; health insurance  
market, risk, and, 158–60
- Uninsured population, 159
- United States: Affordable Care Act, equita-  
ble access, and, 124–25; death rates  
of poor people in, 23; free market in,  
87; gross domestic product per capita  
and infant mortality rate in, 27;  
income distribution and health in,  
18; life expectancy in, 37; median  
and mean household income in, 19;  
poverty guidelines for 48 contiguous  
states and District of Columbia, 26
- Unnecessary services: supplier-induced  
demand and, 145, 147
- Unstable results, in research studies, 25
- US Preventive Services Task Force, 189
- Utah: research on death rates in, 50
- Utility: budget constraint and, 7, 8; defi-  
nition of, 6, 8, 94; expected, 168,  
169, 171; maximizing, 89, 167; risk  
aversion and, 167–69
- Utilization: health plan stipulations and,  
164; of physician services, coinsur-  
ance study on, 106–7
- Vaccinations: herd immunity and, 122,  
130; societal benefit and social loss  
and, 131, 131
- Variable cost, definition of, 64

- Veterans Health Administration (VHA), 46  
von Neumann, John, 167
- Wages: backward-bending supply curve of labor and, 147–48, 148; monopsony structure and, 123
- Waiting time: demand for healthcare and, 90
- Washington Post*, 5
- Wealth: diminishing marginal utility of, 167, 168; expected, 168; marginal utility of, for risk lovers, 170; use of term, 11
- Wealth–health relationship: dynamics within, 11–13; graphing, 13; international studies on, 27–29. *See also* Income–health theories
- Welfare gain, 165
- Welfare loss: insurance coverage and, 165
- Whitehall Study, 27
- Wide distribution of income: health status and, 18
- Willingness to pay: measuring, difficulty in, 86–87
- Workplace: health–wealth relationship and, 12
- World Bank, 28
- World Health Organization, 28
- Zero copayment: excess demand in market with, 128, 129, 130
- Zero economic profits: perfect competition and, 115